Patient characteristics
Characteristic . | DA, n = 174 . | ATRA, n = 176 . |
---|---|---|
Sex, % | ||
Male | 56 | 48 |
Female | 44 | 52 |
Age, y | ||
Median | 38 | 37 |
Range | 1-74 | 1-81 |
% younger than 15 | 13 | 14 |
% 15-55 | 66 | 66 |
% 56-65 | 13 | 9 |
% older than 65 | 9 | 10 |
WBC, per μL | ||
Median | 2300 | 2050 |
Range | 0.6-162 000 | 0.3-69 000 |
Morphology, % | ||
Classical M3 | 76 | 82 |
M3v | 23 | 18 |
Characteristic . | DA, n = 174 . | ATRA, n = 176 . |
---|---|---|
Sex, % | ||
Male | 56 | 48 |
Female | 44 | 52 |
Age, y | ||
Median | 38 | 37 |
Range | 1-74 | 1-81 |
% younger than 15 | 13 | 14 |
% 15-55 | 66 | 66 |
% 56-65 | 13 | 9 |
% older than 65 | 9 | 10 |
WBC, per μL | ||
Median | 2300 | 2050 |
Range | 0.6-162 000 | 0.3-69 000 |
Morphology, % | ||
Classical M3 | 76 | 82 |
M3v | 23 | 18 |
D indicates daunorubicin; A, cytarabine; ATRA, all-trans retinoic acid; WBC, white blood cell count; and M3v, microgranular variant.